Trial intelligence / Profile preview

Pyrotinib in HER2-positive non-breast advanced solid tumors

ChiCTR2000038064Phase 4Recruiting

Sponsor
Jiangsu Provincial Hospital of Traditional Chinese Medicine
Start
Oct 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of pyrotinib in Nonhematologic neoplasms, sponsored by Jiangsu Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: progression-free survival. Started Oct 2020; status: recruiting.

02

Drugs

pyrotinib
03

Conditions

Nonhematologic neoplasms

Beyond the preview

Go deeper on ChiCTR2000038064.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2000038064.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call